ImmunityBio (IBRX) Short-term Investments (2015 - 2026)

ImmunityBio (IBRX) has reported Short-term Investments for 12 consecutive years, with $175.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments rose 18770.57% year-over-year to $175.7 million; the TTM figure through Mar 2026 stood at $175.7 million (up 18770.57% YoY), while the FY2025 annual figure was $154.5 million, up 2321.0% from the prior year.
• Short-term Investments improved to $175.7 million in Q1 2026 per IBRX's latest filing, from $154.5 million in the prior quarter.
• Across five years, Short-term Investments topped out at $197.6 million in Q3 2025 and bottomed at $931000.0 in Q1 2025.
• Historically, Short-term Investments has averaged $52.9 million across 5 years, with a median of $16.0 million in 2025.
• Annual changes were most pronounced in 2023 — Short-term Investments slumped 98.21% — and 2026, when it surged 18770.57%.
• ImmunityBio's Short-term Investments stood at $2.5 million in 2022, then plunged by 60.32% to $1.0 million in 2023, then surged by 532.41% to $6.4 million in 2024, then surged by 2321.0% to $154.5 million in 2025, then advanced by 13.72% to $175.7 million in 2026.
• Business Quant data shows IBRX's Short-term Investments at $175.7 million in Q1 2026, $154.5 million in Q4 2025, and $197.6 million in Q3 2025.